ClinicalTrials.gg
Status unknownNCT03981536Updated Oct 27, 2020

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

A Phase 1 interventional study of AP-101 in Amyotrophic Lateral Sclerosis, sponsored by AL-S Pharma. Status unknown at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-27.

Sponsored by AL-S Pharma · Phase 1, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.

Planned enrollment
61st of 72
18 · median 75
Started
2019
with 4 others
Phase 1
16 of 82
5 open now
Registered
37th of 82
by date
Lead sponsor
2 of 82
AL-S Pharma

Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 61st largest by planned enrollment of the 72 interventional ones that give a count, is one of 5 that started in 2019, is one of 16 in phase 1, and was the 37th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

Single ascending doses of AP-101 will be administered by intravenous (IV) infusion

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • Familial Amyotrophic Lateral Sclerosis
  • Sporadic Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants must adhere to restrictions
  • Female patients of non- due to:

    1. Menopause: spontaneous amenorrhea for at least 12 months not induced by a medical conditions such as anorexia nervosa and not taking medications that induced the amenorrhea (e.g., oral contraceptives, hormones, gonadotropin releasing hormones, anti-estrogens, selective estrogen receptor modulators, or chemotherapy)
    2. Surgical sterilization
  • Have possible, probable, probable laboratory supported or definite and definite familial laboratory-supported ALS in accordance with the El-Escorial criteria
  • Have familial or sporadic ALS.
  • With onset of ALS symptoms, specifically onset of muscle weakness within past 48 months
  • Have slow vital capacity (SVC) of (greater than or equal to) ≥60%
  • If on riluzole, must be on a stable dose
  • If on edaravone, must have completed 2 cycles and are expected to remain on the same dose throughout the study
  • Able to provide . If the patient is not able to provide written consent due to aggravation of disease condition, written informed consent may be provided by a legally authorized representative
  • Have venous access sufficient to allow for blood sampling
  • Have clinical laboratory test results within normal reference range for the population or study site, or results with acceptable deviations that are judged to be not

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, or discontinued from, within the last 30 days, a clinical trial involving an drug or device or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have previously completed or withdrawn from this study
  • Have a history or presence of medical illness including, but not limited to, any cognitive, cardiovascular, hepatic, hematological, renal, endocrine, or psychiatric, or any laboratory abnormality that indicates a medical problem that would preclude study participation
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Show evidence of and/or positive hepatitis C antibody
  • Show evidence of and/or positive hepatitis B surface antigen
  • Are women who are lactating.
  • Have undergone a tracheostomy unless it was removed at least 6 months prior
  • Are on feeding tube, unless the insertion of a feeding tube is considered prophylactic
  • Are on nasal intermittent positive pressure ventilation (NIPPV) >4 hours per day or at the discretion of the medical monitor
  • Have undergone stem cell therapy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    AP-101: Dose Level 1

    Single dose of AP-101

    Drug: AP-101

  • Experimental
    AP-101: Dose Level 2

    Single dose of AP-101

    Drug: AP-101

  • Experimental
    AP-101: Dose Level 3

    Single dose of AP-101

    Drug: AP-101

Interventions

  • DrugAP-101

    Administered by intravenous infusion (IV)

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs)

    A clinical trial AE is any untoward medical event associated with the use of a drug or drug delivery system in humans, whether or not it is considered related to that drug or drug delivery system

    Time frame: Baseline up to day 84

  2. Number of participants with abnormalities in vital signs, clinical laboratory assessments, physical or neurological examinations, or electrocardiograms (ECGs)

    Vital signs include blood pressure, pulse rate, and body temperature

    Time frame: Baseline up to day 84

Secondary outcomes

  1. Maximum Observed Drug Concentration (Cmax)

    In serum

    Time frame: Baseline up to day 84

  2. Time of Maximum Drug Concentration (Tmax)

    In serum

    Time frame: Baseline up to day 84

  3. Area Under the Concentration Time Curve (AUC)

    In serum

    Time frame: Baseline up to day 84

  4. Pharmacokinetic Concentrations in Cerebrospinal Fluid (CSF)

    Taken at screening, and then only one sample per participant post-dose, in the higher level doses

    Time frame: Screening, and at either 1 hour, 4 hours, 24 hours, 48 hours, 72 hours, or 168 hours

07

Study locations

3 sites
  • London Health Sciences Centre, University Hospital
    London, Ontario N6A 5A5, Canada
  • Sunnybrook Health Sciences Centre, Toronto
    Toronto, Ontario M4N 3M5, Canada
  • Montreal Neurological Institute & Hospital
    Montréal, Quebec H3A 2B4, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Nov 2020, 12 months after the start.

Of 40 industry-sponsored phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 12 months is below that.

Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2019
First posted
Jun 11, 2019
StartActual
Oct 10, 2019
Primary completionEst.
Nov 2, 2020
CompletionEst.
Nov 2, 2020
Last update
Oct 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03981536
Lead sponsor
AL-S Pharma
Responsible party
Sponsor
First posted
Jun 11, 2019
Start date
Oct 10, 2019
Primary completion
Nov 2, 2020 (estimated)
Completion
Nov 2, 2020 (estimated)
Last update
Oct 27, 2020

Study contacts

Study Director
study director · AL-S Pharma SA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Episalvan

Start the discussion